GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CureVac NV (NAS:CVAC) » Definitions » PS Ratio

CureVac NV (CureVac NV) PS Ratio : 11.83 (As of May. 15, 2024)


View and export this data going back to 2020. Start your Free Trial

What is CureVac NV PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, CureVac NV's share price is $3.10. CureVac NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.26. Hence, CureVac NV's PS Ratio for today is 11.83.

The historical rank and industry rank for CureVac NV's PS Ratio or its related term are showing as below:

CVAC' s PS Ratio Range Over the Past 10 Years
Min: 8.89   Med: 29.97   Max: 381.11
Current: 11.34

During the past 6 years, CureVac NV's highest PS Ratio was 381.11. The lowest was 8.89. And the median was 29.97.

CVAC's PS Ratio is ranked worse than
55.66% of 999 companies
in the Biotechnology industry
Industry Median: 9.04 vs CVAC: 11.34

CureVac NV's Revenue per Sharefor the three months ended in Dec. 2023 was $0.11. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.26.

Warning Sign:

CureVac NV revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue per Share Growth Rate of CureVac NV was -29.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was -16.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 32.50% per year.

During the past 6 years, CureVac NV's highest 3-Year average Revenue per Share Growth Rate was 96.10% per year. The lowest was -16.20% per year. And the median was 50.90% per year.

Back to Basics: PS Ratio


CureVac NV PS Ratio Historical Data

The historical data trend for CureVac NV's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CureVac NV PS Ratio Chart

CureVac NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - 180.16 54.81 15.95 15.89

CureVac NV Quarterly Data
Dec18 Mar19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.95 25.63 53.44 31.62 15.89

Competitive Comparison of CureVac NV's PS Ratio

For the Biotechnology subindustry, CureVac NV's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CureVac NV's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CureVac NV's PS Ratio distribution charts can be found below:

* The bar in red indicates where CureVac NV's PS Ratio falls into.



CureVac NV PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

CureVac NV's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=3.10/0.262
=11.83

CureVac NV's Share Price of today is $3.10.
CureVac NV's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.26.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


CureVac NV  (NAS:CVAC) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


CureVac NV PS Ratio Related Terms

Thank you for viewing the detailed overview of CureVac NV's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CureVac NV (CureVac NV) Business Description

Address
Friedrich-Miescher-Strasse 15, Tubingen, BW, DEU, 72076
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.